Wisconsin Capital Management LLC Invests $203,000 in Johnson & Johnson (NYSE:JNJ)

Wisconsin Capital Management LLC acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 1,250 shares of the company’s stock, valued at approximately $203,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Catalina Capital Group LLC lifted its holdings in shares of Johnson & Johnson by 22.2% during the third quarter. Catalina Capital Group LLC now owns 8,098 shares of the company’s stock valued at $1,312,000 after purchasing an additional 1,473 shares in the last quarter. Avidian Wealth Enterprises LLC raised its position in Johnson & Johnson by 2.8% in the 3rd quarter. Avidian Wealth Enterprises LLC now owns 16,749 shares of the company’s stock worth $2,714,000 after buying an additional 452 shares during the last quarter. Beacon Financial Advisory LLC lifted its stake in Johnson & Johnson by 1.4% during the 3rd quarter. Beacon Financial Advisory LLC now owns 8,438 shares of the company’s stock valued at $1,367,000 after acquiring an additional 116 shares during the period. Balentine LLC boosted its holdings in shares of Johnson & Johnson by 76.0% during the 3rd quarter. Balentine LLC now owns 7,748 shares of the company’s stock valued at $1,256,000 after acquiring an additional 3,345 shares during the last quarter. Finally, Tobias Financial Advisors Inc. raised its holdings in shares of Johnson & Johnson by 2.0% during the third quarter. Tobias Financial Advisors Inc. now owns 4,529 shares of the company’s stock valued at $734,000 after purchasing an additional 87 shares during the last quarter. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. TD Cowen cut their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating for the company in a research report on Thursday, July 18th. Citigroup upped their price objective on Johnson & Johnson from $180.00 to $185.00 and gave the company a “buy” rating in a research report on Wednesday, October 16th. Daiwa America downgraded Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 23rd. Daiwa Capital Markets cut shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and lowered their price objective for the stock from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Finally, Sanford C. Bernstein boosted their target price on shares of Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. Seven investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $175.00.

Johnson & Johnson Stock Down 0.4 %

NYSE JNJ opened at $157.76 on Thursday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $143.13 and a 12 month high of $168.85. The stock’s 50 day moving average is $162.96 and its 200 day moving average is $155.76. The stock has a market cap of $379.83 billion, a PE ratio of 22.83, a P/E/G ratio of 2.81 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 15th. The company reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.21 by $0.21. The company had revenue of $22.47 billion during the quarter, compared to analysts’ expectations of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. Johnson & Johnson’s quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company posted $2.66 earnings per share. Research analysts predict that Johnson & Johnson will post 9.94 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.14%. The ex-dividend date is Tuesday, November 26th. Johnson & Johnson’s payout ratio is presently 71.78%.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the sale, the vice president now directly owns 18,973 shares of the company’s stock, valued at $3,131,683.38. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.